Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln) plus BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors — making it the first therapy approved for this specific setting. The decision was based on the similarities between papillary-only disease and carcinoma in situ, both of which carry high risks of recurrence and progression when BCG stops working.
A bladder cancer treatment just got a broader reach. The FDA has expanded the indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with BCG to now include adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with high-grade papillary-only tumors. Previously approved only for patients with carcinoma in situ (CIS) with or without papillary tumors, Anktiva becomes the first therapy ever approved specifically for the papillary-only BCG-unresponsive setting.
The FDA's decision leaned on the biological overlap between CIS and high-grade papillary-only disease — both are aggressive urothelial carcinomas that frequently co-exist, can be hard to distinguish pathologically, and carry a high risk of recurrence and progression when BCG alone fails. Rather than requiring a new clinical trial, the agency extrapolated efficacy data from the QUILT 3.032 trial, which underpinned the original approval. The move also aligns with updated NCCN bladder cancer guidelines from March 2026.
Key Takeaways:
Why it matters: For patients whose bladder cancer hasn't responded to BCG — the standard first-line therapy — options have been limited. This expanded approval gives clinicians a validated, bladder-preserving treatment option for a broader group of high-risk patients.
